This study highlighted that the prolonged hyperactivity of CD8+ T cells following DAA treatment may carry substantial long-term consequences including compromised antitumor immunity, a risk of aggressive forms of hepatocellular carcinoma (HCC), increased chances of HCC recurrence [129], and a greater susceptibility to extrahepatic cancers [130]. Here, CD8A is linked to hepatocellular carcinoma.